No argument with that. The completed CLBP phase 3 trial has already guided some precision, as we agree. And it's more than possible RWE could add further refinement to identifying likely responders when data accumulates after approval. Another non-NGS example which gives us great joy is the huge advantage patients with elevated CRP enjoy from Revascor. No genetic analysis required there, just a simple blood test.
NASDAQ hot!!!, page-227
-
- There are more pages in this discussion • 447 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.015(1.49%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $2.005M | 1.991M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14424 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 63643 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |